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As a noninvasive method, exhaled breath condensate (EBC) has gained importance to improve monitoring of lung diseases and to
detect biomarkers. The aim of the study was to investigate, whether erythropoietin (EPO) is detectable in EBC. EBC was collected
from 22 consecutive patients as well as from healthy individuals. Using a multiplex ﬂuorescent bead immunoassay, we detected
EPO in EBC, as well as tumour necrosis factor-α (TNF-α) in 13 out of 22 patients simultaneously (EPO 0.21 ± 0.03 in U/mL and
TNF-α 34.6 ± 4.2 in pg/mL, mean ± SEM). No signiﬁcant diﬀerences for EPO levels or correlation between EPO and TNF-α were
found but TNF-α was signiﬁcantly higher in patients with chronic obstructive pulmonary disease (COPD) than in non-COPD
(obstructive sleep apnoea, OSA, and lung healthy patients). This is the ﬁrst report of detection of EPO in EBC. Due to the small
study size more data is needed to clarify the role of EPO in EBC.
Copyright © 2006 Christian Schumann et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Exhaled breath condensate (EBC) has gained increasing im-
portance in noninvasive monitoring of airway inﬂamma-
tion [1–4]. This technique allows longitudinal sampling of
biomarkers and may be repeated frequently with no diﬃcul-
ties even in patients with limitations to more invasive meth-
ods (ie, severe dyspnoea due to hypoxia) [5, 6]. Dyspnoea is
the most frequent symptom in pulmonary diseases and is of-
ten associated with hypoxemia. Basically, low tissue oxygena-
tion leads to stabilization of transcription factor hypoxia-
inducible factor (HIF)-1α, and consequently production and
secretionoferythropoietin (EPO)andtheexpressionofEPO
receptor (EPOR).
EPO is a 30.4kd glycoprotein, which has a span of 165
amino acids. It has glycosylated chains, which are necessary
forthebiologicalfunction.Additionalorgans,apartfromthe
kidney, liver, and uterus, have been found to secrete EPO, in-
cluding peripheral vascular smooth muscle cells, endothelial
cells, and insulin-producing cells [7]. Several proinﬂamma-
tory cytokines, including tumour necrosis factor (TNF-α),
interleukin 1β (IL-1β), and interleukin 6 (IL-6), also can
lead to increased expression of EPO and EPOR [8, 9]. On
the other hand, EPO directly prevents cellular inﬂammation
by inhibiting several proinﬂammatory cytokines, such as IL-
6, TNF-α, and monocyte chemoattractant protein-1 (MIP)
[8, 9]. Furthermore, EPO might provide vascular protection
by preserving endothelial cell integrity and preventing apop-
tosis and cellular inﬂammation by inhibiting cellular phos-
phatidylserine (PS) membrane exposure and the subsequent
targeting of cells for phagocytosis by macrophages [10]. Ex-
posureofPSisbelievedtocontributesigniﬁcantlytoavariety
ofdiseases,suchasischemicstroke,dementia,Alzheimerdis-
ease, spinal cord injury, and myocardial infarction [10, 11].
RecentlyithasbeenshownthattheEPO/EPORsystemmight
also play a role in hypoxia-induced pulmonary hypertension
[12].
Previously published data showed that the erythropoietic
response did not correlate with the severity of hypoxia, hy-
poxemia, or erythrocytosis [13]. It is still unclear whether
EPO plays a notable role either in patients with perma-
nent hypoxemia (eg, patients with chronic obstructive pul-
monarydisease,COPD)ortransienthypoxemia(eg,patients
with obstructive sleep apnoea, OSA). There is increasing
evidencethatanaemiainchronicinﬂammatorydiseasessuch
as COPD might be caused by EPO resistance. But not in all2 Mediators of Inﬂammation
Table 1: Patient characteristics of the study group. FEV1 = forced
expiratoryﬂowin1second, FEV1/VC =Tiﬀeneauindex, pO2 =par-
tial pressure of oxygen, pCO2 = partial pressure of carbon dioxide.
Age (mean); range (years) 65.9; 43–83
Male/female 15/7
COPD, n 7
OSA, n 7
Lung healthy subjects∗, n 8
FEV1 (mean ±95% Cl), in L 2.2 ±0.41
FEV1/VC (mean ±95% Cl), in % pred 72.4 ±5.81
pO2 (mean ±95% Cl), in mmHg 68.5 ±3.25
pCO2 (mean ±95% Cl), in mmHg 34.7 ±1.67
∗patients with arterial hypertension (n = 2), aortic valve stenosis (n = 1),
atrial ﬁbrillation (n = 2), and stable coronary heart disease (n = 3).
of the anaemic patients with COPD elevated EPO levels were
found [14]. There is a lack of data concerning prevalence of
anaemia in COPD too [15]. Thus it appears that measuring
ofEPOinEBC,asanoninvasivetechnique,gainsimportance
in the future.
T h em a i np u r p o s eo fo u rs t u d yw a st oi n v e s t i g a t e
whether EPO is generally detectable in EBC, as EPO could be
a versatile marker for various pathologic conditions, as well
as for detection of exogenous supply of EPO in competitive
sports or for further treatment strategies in advanced COPD.
METHODS
Subjects
Over a period of 6 weeks, 22 consecutive unselected in- and
outpatients of the Section of Pulmonary Medicine, Univer-
sity of Ulm, Germany, were enrolled into the study. All pa-
tientswererecruitedfromthelungfunctionlabwhileroutine
tests. A detailed overview on patient characteristics is given
in Table 1. From each patient, EBC was collected always in
the morning and additional lung function measurements in-
cluding blood gas analyses were done. All patients breathed
in normal air at standard atmospheric pressure. Written in-
formed consent was obtained from all. The study was ap-
proved by the Local Ethics Committee.
Exhaledbreathcondensatecollection
EBC was collected according to the ATS/ERS Task Force
[16]. We used a condenser, which permitted noninvasive
collection of the nongaseous components of the expira-
tory air (EcoScreen; Jaeger, Germany). The subjects breathed
through a mouthpiece and a two-way nonrebreathing valve,
which also served as a saliva trap. They were instructed to
breathe tidally, wearing a nose clip, for 15 minutes. If the
subjects salivated, they were instructed to swallow. The ob-
tained condensate (approximately 2-3mL in each patient)
was transferred to Eppendorf tubes and immediately stored
at −80◦C.
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Figure 1: TNF-α- and EPO levels in exhaled breath condensate
(EBC) from 13 nonhypoxic subjects in which both markers could
be detected simultaneously, horizontal line = mean.
Cytometricbeadarray
A multiplex chemiluminescent immunoassay system (Im-
mulite, DPC Biermann, Germany) was used to detect EPO
and TNF-α. The measurement was done according to the
manufacturer’s protocol. The use of cytometric bead arrays
has been validated for the use of EBC previously [4]. The de-
tection limit was 0.24mIU/mL for EPO and 1.7pg/mLfor
TNF-α.
Lungfunctionmeasurement
To measure lung function, a bodyplethysmograph was used
(MasterScreen Body; Jaeger GmbH, Germany) and for blood
gas analysis, a radiometer was used (ABL555, Radiome-
ter A/S, Denmark). Lung function (spirometric parameters:
forced expiratory volume in 1 second, FEV1, and inspiratory
vitalcapacity,VC)wasmeasuredaccordingtoEuropeanRes-
piratory Society (ERS) recommendations [17].
Statisticalanalysis
Data were expressed as mean values and standard errors of
mean (SEM). To compare EPO- and TNF-α levels between
subgroups of patients, the Mann-Whitney U test was uti-
lized. A value of P<. 05 was considered statistically sig-
niﬁcant. Statistical analysis was performed with the Statis-
tica software package (StatSoft Inc Tulsa, USA). Graphs were
compiled using the GraphPad Prism Software (GraphPad
Software, Inc, San Diego, USA).
RESULTS
EPO was detected in 15 and TNF-α in 13 out of 22 patients.
In 13 cases, EPO and TNF-α could be detected simultane-
ously (EPO 0.21 ± 0.03U/mL, TNF-α 34.6 ± 4.2i np g / m L ;
mean ± SEM), see Figure 1.
There were no signiﬁcant diﬀerences in EPO levels be-
tween the groups (COPD, OSA, and lung healthy patients,
pooledasnon-COPD),asdisplayedinFigure 2.Additionally,Christian Schumann et al 3
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Figure 2: TNF-α- and EPO levels in EBC. In COPD, TNF-α levels
were signiﬁcantly higher compared to OSA and lung healthy pa-
tients (pooled as non-COPD), calculated using Mann Whitney U
Test, P<. 05 denotes signiﬁcance, horizontal line = mean.
hypoxia and the smoking status did not inﬂuence EPO levels
in EBC. In 2 subjects in which EPO was detectable, TNF-α
was not traceable.
In COPD, TNF-α levels were signiﬁcantly higher than in
OSA and lung healthy patients (pooled as non-COPD, P<
.05), see Figure 2.
Lung function measurement showed normal lung func-
tions in the majority of individuals, as displayed in Table 1,
especially no severe hypoxia or hypercapnia was noted.
DISCUSSION
The use of EBC to monitor inﬂammation in airways is well
documented, and might be expanded to other ﬁelds of di-
agnosis [18–21]. In our study, EBC from 22 consecutive pa-
tients was collected and EPO was detected in 15/22 (68.1%)
patients.
In patients with COPD, we noted a trend towards higher
EPO levels than those with OSA or in lung healthy patients
(pooled as non-COPD), however this was statistically not
signiﬁcant. These were comparable to normal reference val-
ues of EPO in serum (diﬀerences were not signiﬁcant).
Higher EPO levels in COPD might be expected due to
the nature of disease leading to chronic hypoxia. However,
it is unclear if EPO or TNF-α can be expected in EBC in all
individuals at all times. Furthermore, no reliable data exist
concerning the right point in time to measure biomarkers in
EBC.
TNF-α levels in COPD patients were signiﬁcantly higher
than in OSA patients or lung healthy individuals (pooled
as non-COPD). No signiﬁcant correlation of EPO levels
with TNF-α was found. Our results concerning TNF-α were
higher but still in the range of data described previously
[4, 21, 22].
EPO could not be detected in 7 subjects, whereas TNF-α
was not measured in 2 cases in which EPO was found. Even
though the sampling of EBC was strictly performed accord-
ingtotheATS/ERSTaskForceReportonEBC,theinconstant
detection of EPO, respectively, TNF-α might be explained
byunresolvedandpreviouslyreportedmethodologicalprob-
lems like unknown dilution of each biomarker in EBC [16].
The small size of our study can be the cause for these dif-
ferences. On the other hand, temporary hypoxia in OSA pa-
tients seems not to be an adequate stimulus leading to in-
c r e a s e dl e v e l so fE P O .
Reviewing the literature, some attempts have been made
to assess the dilution of substances in EBC samples, which
represent more than 99.9% of condensate volumes. Neither
themeasurementofexhaledvolume,exhaledions,urea,pro-
tein concentration nor the conductance of lyophilised sam-
ples and external dilution markers (for internal or external
standards) could resolve this problem completely [23–27].
To improve the method, combined eﬀorts of all per-
sons involved in collecting and handling of EBC samples
are needed. A standardization of the method to collect EBC
was recently accomplished and published by the European
Respiratory Society (ERS) [16]. Furthermore, more sensitive
analysis methods should be developed and validated, prefer-
ablywithrepeatedmeasurementsofbiomarkers.Thus,many
questionsforinterpretationofEBCdataregardingtheuncer-
tain source of condensate solutes and the variable dilution of
respiratory droplets fromcondensedwatervapourhave tobe
answered.
In severe COPD, anaemia is present up to 23% and
higher EPO levels are expectable as disease progresses [15].
Based on these data, new treatment strategies could be de-
veloped regarding the role of EPO in advanced COPD. It is
still unclear whether higher EPO levels or EPO resistance de-
terminesanaemiainthesepatients.EBCasanoninvasiveand
easy-to-use diagnostic method could help to monitor disease
state by determination of characteristic biomarkers as a diag-
nostic tool or to control the treatment success of patients.
There is ample evidence that a complex network of in-
ﬂammatory cytokines and chemokines has a prominent role
in mediation and perpetuation of the processes of acute lung
injury [28].
Detection of EPO in EBC might further be a useful tool
in a variety of diseases, however especially in conditions with
reduced tissue oxygenation, for example, COPD, pulmonary
hypertension, various states of shock and myocardial infarc-
tion, but might develop into a useful noninvasive tool for
detection of exogenous supply of EPO in competitive sports
on the one hand, and for monitoring training eﬀects in le-
gal sports on the other hand, after data on EPO detection
are bolstered by other groups and larger trials. In this con-
text, noninvasive measurement of EPO in EBC (eg, in me-
chanically ventilated patients) might provide new insights
into mechanisms of disease and might develop into a tool
which allows to early counteract undesirable eﬀects of tissue
hypoxia apart from clinical shock as, for example, induction
of apoptosis or inﬂammation. For example, EPO has been
linked to cardiac ischemia and reperfusion injury and it has
been shown that administration either before or during my-
ocardialischemia-reperfusioncanprotectagainstmyocardial
cell apoptosis and decrease infarct size, resulting in enhanced
cardiac function and improved left ventricular contractility
in a rabbit model of infarction [29].4 Mediators of Inﬂammation
Our results are further in contrast to recent publica-
tions that measured levels of biomarkers in EBC vary among
each other, due to variable dilution of the ELF droplets with
condensed water vapour (approximately up to 20 000-fold)
as compared to serum levels [25, 30]. But up till now, no
systematic examinations exist to resolve this problem com-
pletely. The detection of EPO in EBC is, even in that high
amount, somewhat unexpected, following the current per-
ception that molecular size limits the detection of volatile
compounds. Review existing literature shows that this hy-
pothesis has to be revised. More complex proteins (ie, ker-
atins with 40–52kd), with similar or larger molecular weight
compared to EPO (30.4kd),couldbedetectedinEBC[31,
32]. But these ﬁndings are still not validated in larger popu-
lations.
To the best of our knowledge, this is the ﬁrst description
ofdetection ofEPO in EBCinpatients with COPDand OSA,
however the clinical signiﬁcance remains unclear.
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